MedPath

Multiple Study of Electroaccpuncture in ARDS

Not Applicable
Not yet recruiting
Conditions
Sepsis
Acute Respiratory Distress Syndrome
Interventions
Device: Acupuncture needles
Registration Number
NCT06278675
Lead Sponsor
Nanjing University of Traditional Chinese Medicine
Brief Summary

In order to clarify the clinical efficacy of electroacupuncture on inhibiting systemic inflammatory response, improving respiratory mechanics parameters and prognosis in patients with sepsis-related ARDS.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
264
Inclusion Criteria
  • Meet the diagnostic criteria of the Surviving Sepsis Campaign: Updated International Guidelines for the Treatment of Sepsis and Septic Shock 2021
  • Meet the diagnostic criteria of the European Society of Critical Care Medicine (ESICM) Guidelines for Acute Respiratory Distress Syndrome: Definition, Phenotype and Respiratory Support Strategies
  • Age >18 years
  • Expected duration of mechanical ventilation>48 hours
  • Expected ICU stay of more than 7 days
  • Signed informed consent.
Exclusion Criteria
  • Participated in other clinical trials
  • Pregnant, lactating or miscarriage
  • Patients with disseminated tumors or tumors receiving chemotherapy and other special treatments
  • Alcohol abuse
  • Severe cardiovascular, brain, liver, kidney, psychiatric diseases, diabetes, multiple system atrophy, cauda equina injury or myelopathy
  • Systolic blood pressure < 90mmHg within 2 hours before the start of the study
  • Severe burns or severe skin diseases
  • Pacemaker placement, metal allergy or severe needle sickness
  • Abnormal coagulation function

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupAcupuncture needlesExperimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
Primary Outcome Measures
NameTimeMethod
Respiratory mechanics indicators 1Day 0、day 7

Oxygenation index(P/F)

Respiratory mechanics indicators 3Day 0、day 7

Driving pressure(DP)

Respiratory mechanics indicators 2Day 0、day 7

Respiratory rate(RR)

Respiratory mechanics indicators 4Day 0、day 7

Positive end expiratory pressure(PEEP)

Respiratory mechanics indicators 5Day 0、day 7

Mechanical ventilation days(MV days)

Respiratory mechanics indicators 6Day 0、day 7

Mechanical ventilation free days(MV free days)

Respiratory mechanics indicators 7Day 0、day 7

Extubation situation

Secondary Outcome Measures
NameTimeMethod
All-cause mortality to day 60Up to 60 days

The prognosis of patients on the 60th days will be counted.

ECMO applicationsDay 0 to day 7

The duration of extracorporeal membrane oxygenation will be recorded.

Sedation and analgesiaDay 0、day 7

RASS score

Analgesic drug useDay 0、day 7

The dose and duration of analgesic medication will be recorded.

Inflammatory factorsDay 0、day 7

IL-1β、IL-6、IL-2、IL-4、IL-5、IL-8、IL-10、IL-17、IL-12、 IFN-γ、IFN-α、TNF-α.

All-cause mortality to day 28Up to 28 days

The prognosis of patients on the 28th days will be counted.

Vasoactive drugs applicationsDay 0 to day 7

The duration of vasoactive drug use will be recorded.

CRRT applicationsDay 0 to day 7

The duration of continuous renal replacement therapy will be recorded.

ICU-free days2 year

The prognosis of patients ICU length of stay will be counted.

Hospital-free days2 year

The prognosis of patients total length of stay will be counted.

CD4、CD8、CD4/CD8Day 0、day 7

Flow cytometry will be used to detect serum CD4, CD8 and CD4/CD8 levels.

Sedative drug useDay 0、day 7

The dose and duration of sedative medication will be recorded.

Trial Locations

Locations (1)

Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath